



Oriola changes its segment reporting and publishes preliminary figures

Oriola Corporation Stock Exchange Release 31 October 2023 at 8:40 a.m. EET

Oriola changes its segment reporting and publishes preliminary figures

Oriola is updating its segment reporting to reflect the new strategy, announced on 31 October 2023, and to improve transparency. Oriola's two reporting segments as of 1 January 2024 will be:

- **Distribution segment** consisting of pharmaceutical logistics and dose dispensing services.
- **Wholesale segment** consisting of wholesale of traded goods and over-the-counter (OTC) products, parallel import and special licensed medicines, as well as advisory services.

Oriola's restated segment information for the financial years 2023 and 2022 will be published during Q1 2024. The restated figures are unaudited. As preliminary, unaudited financial information for the new segments, Oriola provides following figures, including dose dispensing business in Sweden:

- Distribution segment's net sales in 2022 were EUR 1,168.9 million and adjusted EBIT was EUR 21.6 million.
- Wholesale segment's net sales in 2022 were EUR 351.1 million and adjusted EBIT was EUR 6.5 million.
- Eliminated internal sales between segments in 2022 were EUR 4.5 million and non-allocated group items' effect to adjusted EBIT was EUR -8.4 million.

Oriola's Interim Report for January-March 2024 will be prepared according to the new segment reporting and published on 26 April 2024.

Oriola Corporation

Further information:

Timo Leinonen, CFO
Email: timo.leinonen@oriola.com

Distribution:

Nasdaq Helsinki Ltd
Key media